VRAXHealthcare · BiotechnologyVRAX Stock Forecast: Virax Biolabs Group Ltd. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Virax Biolabs Group Ltd. hold a median 12-month price target of $25 — +865.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 15 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
VRAX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Virax Biolabs Group Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
VRAX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VRAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +865.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | $3.00 → $1.00 |
| 31 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRAX appears on the weeks it earns a place.
VRAX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Sept 2026, Virax Biolabs Group Ltd. returned −84.0% against +15.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VRAX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Virax Biolabs Group Ltd. (VRAX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- 171.3×
- Price / book
- 0.2×
- EV / EBITDA
- 0.8×
Cheaper than 78% of US stocks
Cheaper than 3% of US stocks
Cheaper than 89% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- 684.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −35264.9%
- Net margin
- 61.9%
Higher than 98% of US stocks
Higher than 1% of US stocks
Higher than 97% of US stocks
- Return on equity
- −78.6%
- Return on assets
- −54.2%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Virax Biolabs Group Ltd. (VRAX) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Virax Biolabs Group Ltd. has a market value of $2.1M and an enterprise value of −$4.8M.
Trailing P/E: −0.2×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Virax Biolabs Group Ltd. employs 26 people.
Data provided by Twelve Data
VRAX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Virax Biolabs Group Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about VRAX stock
What is the VRAX stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Virax Biolabs Group Ltd. have a median 12-month price target of $25, with estimates ranging from $25 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VRAX stock a buy right now?
Of the 1 analysts covering Virax Biolabs Group Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Virax Biolabs Group Ltd. 16 out of 100 across roughly 4,600 US stocks as at 15 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VRAX?
As at 15 Sept 2026, Virax Biolabs Group Ltd. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
Will VRAX stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +865.3% from the last close, and Ticker Nerd's factor model ranks Virax Biolabs Group Ltd. 16 out of 100 as at 15 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VRAX stock forecast for 2030?
No analyst covering Virax Biolabs Group Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.
How has VRAX stock performed over the past year?
Virax Biolabs Group Ltd. returned -84.0% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Virax Biolabs Group Ltd. do?
Virax Biolabs Group Ltd. is a biotechnology company focused on immune response detection and the diagnosis of viral diseases.
About Virax Biolabs Group Ltd.
Virax Biolabs Group Ltd. is a biotechnology company focused on immune response detection and the diagnosis of viral diseases. Its core work centers on T cell-based in vitro diagnostic technologies and immunology profiling tools designed to help assess immune risk related to viral and immune-mediated conditions. The company develops and commercializes diagnostic test kits and related med-tech products under the ViraxClear brand, while its ViraxImmune platform is intended to support immune profiling and the evaluation of post-viral syndromes such as Long COVID and other chronic immune dysfunction states. Virax Biolabs Group Ltd. serves healthcare and research-oriented markets where viral detection, immune assessment, and diagnostic support are important, positioning the company within the broader biotechnology and in vitro diagnostics sectors. The company is headquartered in BioCity Glasgow, United Kingdom.
CEO Mr. James Foster · 26 employees · United Kingdom · https://viraxbiolabs.com